%0 Journal Article %A Alan C. Kwan %A Trevor Nguyen %A Elizabeth H. Kim %A Emmanuella Demosthenes %A Gerran Salto %A Eric Luong %A Pranoti Hiremath %A Debiao Li %A Daniel S. Berman %A Jignesh Patel %A Susan Cheng %T Ultrasonic Texture Analysis Identifies Cardiac Microstructural Alterations in Immune-Inflammatory Disease %D 2020 %R 10.1101/2020.06.10.20125443 %J medRxiv %P 2020.06.10.20125443 %X Background Echocardiographic texture analysis using the signal intensity coefficient (SIC) can identify fibrosis-associated microstructural changes. This approach has not been tested in immune-inflammatory disease states such as myocarditis or transplant rejection.Methods Retrospective pilot analysis using the SIC was performed in populations including myocarditis (n=5), acute left anterior descending coronary artery STEMI (n=6), severe aortic stenosis with normal ejection fraction (n=7), ATTR amyloidosis (n=6), and cardiac transplant patients undergoing biopsy including patients with active rejection on histopathology (n=22), patients with history of rejection but no current rejection (n=15), and patients without history of or current rejection (n=5), and a healthy control group (n=28).Results Decreased SIC was noted in the myocarditis and transplant rejection populations, with decreasing SIC by presence and history of rejection. Consistent with prior literature, the SIC was elevated in cardiac conditions associated with fibrosis.Conclusions The SIC may be able to capture microstructural changes associated with immune-inflammatory processes such as cardiac transplant rejection and myocarditis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health contract N01−HC−25195 HHSN268201500001I and grants T32HL116273, R01 HL 077477, R01HL131532, R01HL134168, R01 DK080739, R01HL126136, R01 HL 080124, R01 HL 077477, and R01 HL 70100; the Barbra Streisand Women's Cardiovascular Research and Education Program; and, the Erika Glazer Women's Heart Health Project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of Cedars-Sinai Medical Center approved all protocols.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe−identified data are available upon request and in accordance with standard institutional data sharing agreements. %U https://www.medrxiv.org/content/medrxiv/early/2020/06/12/2020.06.10.20125443.full.pdf